Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8YX1

CD40 in complex with Bleselumab Fab

8YX1 の概要
エントリーDOI10.2210/pdb8yx1/pdb
分子名称Bleselumab, heavy chain, Bleselumab, light chain, Tumor necrosis factor receptor superfamily member 5, ... (4 entities in total)
機能のキーワードcd40, dacetuzumab, bleselumab, agonist activity, tumor necrosis factor, immune system
由来する生物種Homo sapiens
詳細
タンパク質・核酸の鎖数6
化学式量合計134944.52
構造登録者
Caaveiro, J.M.M.,Fernandez-Perez, J.,Tsumoto, K. (登録日: 2024-04-01, 公開日: 2024-05-08, 最終更新日: 2024-11-06)
主引用文献Asano, R.,Nakakido, M.,Perez, J.F.,Ise, T.,Caaveiro, J.M.M.,Nagata, S.,Tsumoto, K.
Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab.
Biochem.Biophys.Res.Commun., 714:149969-149969, 2024
Cited by
PubMed Abstract: CD40 is a member of the tumor necrosis factor receptor superfamily, and it is widely expressed on immune and non-immune cell types. The interaction between CD40 and the CD40 ligand (CD40L) plays an essential function in signaling, and the CD40/CD40L complex works as an immune checkpoint molecule. CD40 has become a therapeutic target, and a variety of agonistic/antagonistic anti-CD40 monoclonal antibodies (mAbs) have been developed. To better understand the mode of action of anti-CD40 mAbs, we determined the X-ray crystal structures of dacetuzumab (agonist) and bleselumab (antagonist) in complex with the extracellular domain of human CD40, respectively. The structure reveals that dacetuzumab binds to CD40 on the top of cysteine-rich domain 1 (CRD1), which is the domain most distant from the cell surface, and it does not compete with CD40L binding. The binding interface of bleselumab spread between CRD2 and CRD1, overlapping with the binding surface of the ligand. Our results offer important insights for future structural and functional studies of CD40 and provide clues to understanding the mechanism of biological response. These data can be applied to developing new strategies for designing antibodies with more therapeutic efficacy.
PubMed: 38657446
DOI: 10.1016/j.bbrc.2024.149969
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.7 Å)
構造検証レポート
Validation report summary of 8yx1
検証レポート(詳細版)ダウンロードをダウンロード

229183

件を2024-12-18に公開中

PDB statisticsPDBj update infoContact PDBjnumon